For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

In this Saturday edition of BI Today, we're talking about the end of a GLP-1 shortage, and Hollywood's awards season.

“Jack of all trades” is a saying implying someone who has skills in different areas. The newer GLP-1 medications may qualify as such. The GLP-1s include semaglutide (Ozempic, Wegovy) and the ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...